clinical complexity slows uptake Long-acting or micro-dosages (e.g., monthly injections, microneedle patches) What changes: Improved tolerability, better adherence Where it moves : Possibly back toward DTC models if access outpaces infra Strategic shift: Less patient burden, potential wedge for intermediaries Risk: Manufacturing lag or cost may stall rollout
Experiments using these DPP-IV inhibitors in animals showed that GLP-1 degradation could be prevented, and glucose tolerance was improved [31,32]
Recent headlines, like the Wall Street Journals coverage, highlight surging interest in new medications, along with growing concerns from the FDA regarding the use of compounded and unapproved versions of GLP-1-based treatments
This study did not generate or analyze custom code
Statistical analysis Data were preliminarily tested for normality with KSmirnov test, and descriptive data were accordingly expressed as means.d., or median with interquartile range